Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

Abstract

determined that Girija Dasmahapatra, the first author of the above-mentioned article, engaged in research misconduct by falsifying and/or fabricating data that appeared in the 2012 article (2). Specifically, respondent reused, and/or relabeled Western blot panels and mouse images and claimed they represented different controls and/or experimental results in: Figs. 3A (JNK and Tubulin), 3B (Tubulin-scram), 3D (Tubulin-pUSE-AKT cl.3), and 6B (CFZ þ obato; ref. 2). The matter was reviewed by members of the AACR Publications staff and the MCT editors, who agree that the figure manipulation present in the article merits retraction.

Fbw7 Inhibits the Progression of Activated B-Cell Like Diffuse Large B-Cell Lymphoma by Targeting the Positive Feedback Loop of the LDHA/lactate/miR-223 Axis

“…Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) which derived from mature B cells and accounts for 30% to 35% of all nodal lymphomas ( 1 , 2 ). Based on generation sequencing and cell-of-origin, DLBCL could be stratified into two molecular subtypes, the activated B cell (ABC) type and the germinal center B cell (GCB) type.…”